8-K
filed May 19, 2026, 5:07 PM ET
ticker JAGX
CIK 0001585608
other material
confidence high
sentiment neutral
materiality 0.75
Jaguar Health, Inc. (JAGX): debt financing — Jaguar Health exchanges $22.7M in royalty interests for Series Q Preferred Stock
Jaguar Health, Inc.
- Uptown Capital: $12.5M royalty reduction for 500 Series Q shares.
- Streeterville: $3.7M reduction (148 shares) + $6.5M reduction (260 shares).
- Series Q carries 10% annual preferred return payable in additional Series Q shares.
- Company can exchange Series Q for common at Minimum Price; 9.99% ownership cap.
- Restrictive covenants include equity issuance limit and majority-holder consent rights.
Key facts
Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Jaguar Health, Inc. amended debt of $12 million with Streeterville Capital, LLC.
- Principal
- $12 million
- Counterparty
- Streeterville Capital, LLC
- Event
- amendment
Exact text from the filing
22, 2020, Jaguar Health, Inc. (the “Company”) sold to Uptown Capital, LLC(f/k/a Irving Park Capital, LLC) (“Uptown”) a royalty interest in the original principal amount of $12 million (as amended, the “December 2020 Royalty Interest”). On May 19, 2026, the Company entered into a privately negotiated exchange agreement (the “Uptown Series Q Exchange Agreement”)
View on SEC.gov
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Jaguar Health, Inc. amended debt of $12 million with Uptown Capital, LLC.
- Principal
- $12 million
- Counterparty
- Uptown Capital, LLC
- Event
- amendment
Exact text from the filing
22, 2020, Jaguar Health, Inc. (the “Company”) sold to Uptown Capital, LLC(f/k/a Irving Park Capital, LLC) (“Uptown”) a royalty interest in the original principal amount of $12 million (as amended, the “December 2020 Royalty Interest”). On May 19, 2026, the Company entered into a privately negotiated exchange agreement (the “Uptown Series Q Exchange Agreement”)
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Jaguar Health, Inc.: Filed Certificate of Designation for Series Q Preferred Stock, establishing preferences, rights, and limitations (effective 2026-05-19).
- Change
- charter amendment
- Effective
- 2026-05-19
Exact text from the filing
The preferences, rights, limitations and other matters relating to the Series Q Preferred Stock are set forth in the Certificate of Designation, which the Company filed with the Secretary of State of the State of Delaware on May 19, 2026. The Certificate of Designation became effective with the Secretary of State of the State of Delaware upon filing.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Jaguar Health, Inc. entered into Uptown Series Q Exchange Agreement with Uptown Capital, LLC (f/k/a Irving Park Capital, LLC) valued at $12,500,000 reduction in the outstanding balance (effective 2026-05-19).
- Action
- entry
- Counterparty
- Uptown Capital, LLC (f/k/a Irving Park Capital, LLC)
- Value
- $12,500,000 reduction in the outstanding balance
- Effective
- 2026-05-19
Exact text from the filing
On May 19, 2026, the Company entered into a privately negotiated exchange agreement (the "Uptown Series Q Exchange Agreement") with Uptown. Pursuant to the Uptown Series Q Exchange Agreement, the Company issued 500 shares of Series Q Perpetual Preferred Stock (the "Series Q Preferred Stock") to Uptown in exchange for a $12,500,000 reduction in the outstanding balance of the December 2020 Royalty Interest.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Jaguar Health, Inc. entered into Second Streeterville Series Q Exchange Agreement with Streeterville Capital, LLC valued at $6,500,000 reduction in the outstanding balance (effective 2026-05-19).
- Action
- entry
- Counterparty
- Streeterville Capital, LLC
- Value
- $6,500,000 reduction in the outstanding balance
- Effective
- 2026-05-19
Exact text from the filing
and (ii) a privately negotiated exchange agreement (the "Second Streeterville Series Q Exchange Agreement"; together with the Uptown Series Q Exchange Agreement and the First Streeterville Series Q Exchange Agreement, collectively, the "CVP Exchange Agreements") also with Streeterville, pursuant to which the Company issued 260 shares of Series Q Preferred Stock to Streeterville in exchange for an additional $6,500,000 reduction in the outstanding balance of the August 2022 Royalty Interest.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Jaguar Health, Inc. entered into First Streeterville Series Q Exchange Agreement with Streeterville Capital, LLC valued at $3,700,000 reduction in the outstanding balance (effective 2026-05-19).
- Action
- entry
- Counterparty
- Streeterville Capital, LLC
- Value
- $3,700,000 reduction in the outstanding balance
- Effective
- 2026-05-19
Exact text from the filing
On May 19, 2026, the Company entered into (i) a privately negotiated exchange agreement (the "First Streeterville Series Q Exchange Agreement") with Streeterville, pursuant to which the Company issued 148 shares of Series Q Preferred Stock to Streeterville in exchange for a $3,700,000 reduction in the outstanding balance of the August 2022 Royalty Interest
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.